Carbonic anhydrase IX (CA IX)

Overview

Carbonic anhydrase 9 (CA9), also known as Carbonic anhydrase (CA) IX, is a membrane-associated enzyme in the Carbonic anhydrase (CA) family. It is widely recognized as a hypoxia-associated marker and a cancer-relevant protein because of its role in regulating tumor pH and supporting survival in low-oxygen microenvironments. By contributing to acid–base balance at the cell surface, CA9 can help tumor cells adapt to hypoxia, promote aggressive behavior, and influence response to therapy.

In biomedical research, CA9 is studied both as a biomarker and as a therapeutic target. Its expression is often linked to invasive phenotypes and treatment resistance in solid tumors, including renal cell carcinoma, triple-negative breast cancer, anal squamous cell carcinoma, and other malignancies such as colorectal, head/neck, melanoma, and prostate tumors. Because of its tumor-associated expression pattern, CA9 has also been explored for molecular imaging and for selective inhibition strategies, including combinations with other cancer-associated enzymes such as Carbonic anhydrase (CA) XII.

Recent Publications Summary

Recent studies have continued to position carbonic anhydrase IX (CA IX) as a prominent tumor-associated target for both inhibitor development and molecular imaging. Several medicinal chemistry programs reported new sulfonamide-based scaffolds with strong CA IX selectivity, including diazo and pyrazole-carboxamide-linked benzenesulfonamides, where a 3,4-dichloro-substituted compound achieved very high potency against hCA IX (K_I = 1.8 nM) and outperformed acetazolamide 42410713Jul. In a related effort, bis-triazole-linked benzenesulfonamides showed nanomolar inhibition of hCA IX/XII, with lead compounds 2g and 4g also reducing the antiproliferative effects of azacitidine and sorafenib in cancer cells under normoxic and hypoxic conditions, supporting a chemosensitizing role for CA IX inhibition 42059120Apr.

CA IX has also been explored extensively in imaging and theranostic radiopharmaceuticals, particularly for clear cell renal cell carcinoma. A SuFEx-modified PET probe, [68Ga]Ga-SF-DPI-4452, retained strong tumor uptake while markedly reducing gastrointestinal accumulation, improving tumor-to-background contrast relative to the parent tracer 42102316May. Similarly, the novel theranostic ligand NYM074 was developed for dual labeling with 68Ga and 177Lu, with preclinical evaluation in OS-RC-2 xenografts and mice showing successful radiolabeling, high serum stability, CAIX binding, and imaging/therapeutic potential 42008867Apr. Another dual-targeting strategy combined CA IX with Fibroblast Activation Protein alpha (FAP): the PEG4-modified heterodimeric radioligand FC showed high FAP affinity, increased tumor uptake in FAP- or CAIX-positive models, and strong tumor accumulation after 177Lu labeling, with complete tumor suppression in a mouse model and no obvious organ toxicity 42367011Jun.

Beyond drug and tracer development, CA IX was also examined in disease biology and biomarker studies. In pediatric gliomas and glioneuronal tumors, CAIX and immune response biomarkers were assessed for associations with clinical outcomes, reflecting interest in its hypoxia-linked role in the tumor microenvironment 42340514Jun. In triple-negative breast cancer, sequential invasion assays identified CA IX as a driver of invasiveness in epithelial tumor subpopulations, which were described as chemotherapy-resistant and stem cell-like, with distinct invasive phenotypes linked to markers such as Cadherin 1 (CDH1) and Vimentin (VIM) 42013067Apr. CA9 was also evaluated as a prognostic marker in anal squamous cell carcinoma treated with definitive (chemo)radiotherapy 42090844May, and in hepatocellular carcinoma studies, CA9 emerged among candidate genes connected to kaempferol’s effects on glycolysis, with knockdown experiments used to probe its contribution to metabolic regulation downstream of the AKT-mTOR pathway and Protein kinase B (PKB) signaling 42322592Jun.

What Changes, What Holds

1. CA IX inhibition is becoming more selective and more useful as a chemosensitizing strategy
REINFORCES New inhibitor series sharpen the established therapeutic theme rather than changing it: CA IX remains a druggable hypoxia-associated target, but the main advance is better potency and selectivity, with some compounds also enhancing the activity of existing anticancer agents under both oxygenated and hypoxic conditions 42410713Jul42059120Apr. That supports CA IX as a combination-therapy lever, while leaving open whether these chemopotentiating effects will translate beyond preclinical models.

2. CA IX-targeted imaging is moving toward cleaner contrast and dual-purpose theranostics
REINFORCES Radiotracer work continues to extend the established imaging role of CA IX, especially in clear cell renal cell carcinoma, by improving biodistribution and adding therapeutic labeling options 42102316May42008867Apr. The dual-targeting FAP/CAIX approach also strengthens the idea that CA IX can be paired with other tumor markers to improve uptake and treatment reach 42367011Jun. What remains unsettled is not whether CA IX can be imaged, but which tracer design best balances tumor retention, background clearance, and safety.

3. CA IX remains a biologically relevant marker, but its prognostic value still depends on context
REINFORCES These studies do not revise the baseline view of CA9 as a hypoxia-linked biomarker in aggressive solid tumors; instead, they broaden the list of settings in which that association is being tested and suggest that CA IX may help stratify invasive or treatment-resistant subpopulations 42340514Jun42013067Apr. The anal squamous cell carcinoma and hepatocellular carcinoma findings are consistent with a marker-and-mechanism role, but they also show that clinical utility is still disease-specific and not yet standardized 42090844May42322592Jun.

Overview update candidates: improved CA IX-selective inhibitors with chemosensitizing potential; cleaner CA IX PET/theranostic tracers and dual-targeting radioligands; broader but still context-dependent biomarker/prognostic use.